{
  "ticker": "RAC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959922",
  "id": "02959922",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0856",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwt2wgwbdpbs.pdf",
  "summary": "- **First patient dosed safely** with RC220 + doxorubicin combination in Phase 1 solid tumour trial.  \n- **No dose-limiting side effects** observed.  \n- **Trial design**: Open-label, multi-site (Australia, Hong Kong, South Korea), Bayesian approach for flexibility.  \n- **Next steps**: Stage 1 (dose escalation, n=33) to determine safety/MTCD; Stage 2 (n=20) to assess efficacy/cardioprotection.  \n\n*Note: No direct material impact on immediate trading/capital structure; primarily clinical progress update.*",
  "usage": {
    "prompt_tokens": 1900,
    "completion_tokens": 124,
    "total_tokens": 2024,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T23:14:52.611345"
}